The Patient-reported Disease Burden in Adults with Atopic Dermatitis: A Cross-sectional Study in Europe and Canada.
Cross-sectional data on patient burden in adults with atopic dermatitis (AD) from real-world clinical practice are limited. This study compared patient-reported burden associated with adult AD across severity levels from clinical practices in Canada and Europe. This study included adults (18-65 years) diagnosed with AD by dermatologists, general practitioners, or allergists. Participants categorized as mild (n = 547; 37.3%), moderate (n = 520; 35.4%), or severe (n = 400; 27.3%) based on Investigator's Global Assessment completed a questionnaire that included pruritus and pain numerical rating scales, PO-SCORAD itch and sleep visual analog scales, Dermatology Life Quality Index (DLQI), and the Hospital Anxiety and Depression Scale (HADS). Participants were also stratified by inadequate efficacy/intolerance/contraindication to cyclosporine (Cyclo; n = 62 [4 mild, 18 moderate, 40 severe]) and any systemic immunomodulatory agent (IMM; n = 104 [13 mild, 31 moderate, 60 severe]) and compared with the severe group excluding participants identified as Cyclo/IMM. Age was similar across severity groups; the proportion of females was higher in the mild group relative to severe (61.2% vs. 50.5%; P < 0.001). Compared with moderate and mild, participants with severe AD had more comorbidities, higher itch and pain severity, worse sleep, and higher levels of anxiety and depression (all P < 0.001). Mean ± SD DLQI score among participants with severe AD (16.2 ± 6.9) showed a large effect on quality-of-life that was higher than those with moderate (10.2 ± 6.3) and mild (5.5 ± 4.9) (both P < 0.001). The burden among Cyclo and IMM subgroups was generally similar to that of participants with severe AD. Adults with AD reported a substantial burden across multiple domains that was significantly higher in those with severe disease. The burden among participants in the Cyclo/IMM subgroups was similar to those with severe AD.